Rani Therapeutics up on starting osteoporosis treatment study

Rani Therapeutics Holdings

23/03/2022 15:47

** Shares of drug developer  RANI.O  rise 2.3% to $13.50
    ** Co begins early-stage study of its experimental treatment
of osteoporosis, RT-102  urn:newsml:reuters.com:*:nGNX3zgXjj
    ** RT-102 is an oral formulation of parathyroid hormone
(PTH); PTH regulates calcium levels in the blood and helps in
bone building
    ** First subject has been administered RT-102 in the study,
which is being conducted in Australia
    ** Study will evaluate RT-102 administered in healthy adult
women volunteers
    ** Stock down ~17% YTD, including session moves

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))